Plus Therapeutics (NASDAQ:PSTV) Shares Down 1.3% – Here’s Why

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) fell 1.3% during mid-day trading on Monday . The stock traded as low as $1.22 and last traded at $1.22. 5,433 shares traded hands during trading, a decline of 77% from the average session volume of 23,247 shares. The stock had previously closed at $1.24.

Analyst Upgrades and Downgrades

PSTV has been the topic of several research reports. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Plus Therapeutics Price Performance

The firm has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.35. The company has a market cap of $7.19 million, a PE ratio of -0.48 and a beta of 0.70.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.